Morningstar

CapsoVision Shares Rise on FDA Application for AI Tool in Swallowable Camera

Provided by Dow Jones

By Adriano Marchese 




  CapsoVision shares rose after the company said it has submitted to U.S. health regulators its new artificial-intelligence-assisted reading tool for its CapsoCam Plus endoscopy system, which uses a swallowable camera. 



  Shares rose 11% to $12.91 midday Tuesday. 



  The commercial-stage medical-technology company said late Monday that it has submitted an application to the Food and Drug Administration for its proprietary AI-assisted module for its CapsoCam Plus. 



  CapsoVision said the addition of this reading tool will improve the detection of clinically significant pathology, and can help doctors spot small-bowel problems more accurately and review images more quickly. 



  Once it receives regulatory clearance, the Saratoga, Calif., company intends to begin U.S. commercialization activities, it said. 





  Write to Adriano Marchese at adriano.marchese@wsj.com 





  (END) Dow Jones Newswires



  December 30, 2025 12:12 ET (17:12 GMT)


Copyright (c) 2025 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
5 Stocks to Sell for Tax-Loss Harvesting 
 
Plus, earnings season kicks off with big banks. 
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
33 Undervalued Stocks to Buy Before the Market Shifts Again
 
Here’s the new list of Morningstar’s top analyst picks for the fourth quarter of 2026. 
 
 
Susan Dziubinski and Tori Brovet 
 
 
 
What’s Ahead for Stocks This Quarter—and Where to Invest
 
Morningstar’s chief market strategist and economist share their outlooks for the fourth quarter of 2026. 
 
 
David Sekera, CFA, Preston Caldwell, and Susan Dziubinski 
 
 
 
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
 
Even short-term muni funds aren’t totally immune from losses. 
 
 
Amy C. Arnott, CFA 
 
 
 
Where to Find Durable Dividends in Today’s Stock Market
 
In tough times for equity income, investors must beware of yield traps.  
 
 
Dan Lefkovitz 
 
 
 
 

			Sponsor Center